ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.35 ^USD	+43.84%		+39.47%	+46.41%

Apr. 26	Transcript : ImmunityBio, Inc. - Special Call
Apr. 25	ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	CI

ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 09, 2023 at 06:12 am EST

ImmunityBio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.082 million compared to USD 0.118 million a year ago. Net loss was USD 95.58 million compared to USD 110.94 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.28 a year ago.
For the nine months, sales was USD 0.483 million compared to USD 0.167 million a year ago. Net loss was USD 349.8 million compared to USD 308.35 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 0.77 a year ago.

Latest news about ImmunityBio, Inc.

Transcript : ImmunityBio, Inc. - Special Call	Apr. 26
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	Apr. 25	CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer	Apr. 23	MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	Apr. 23	MT
Top Premarket Gainers	Apr. 23	MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva	Apr. 23	DJ
US FDA approves ImmunityBio's bladder cancer therapy	Apr. 22	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Apr. 22	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	Apr. 22	RE
ImmunityBio Files Mixed Shelf	Apr. 17	MT
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	Mar. 25	MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
ImmunityBio Announces Data from A Phase 1 Pilot Study	Mar. 05	CI
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	Feb. 21	MT
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21	CI
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	Feb. 05	CI
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	Jan. 02	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jan. 02	MT
ImmunityBio Secures $320 Million Investment From Oberland Capital	Jan. 02	MT
Sector Update: Health Care	Jan. 02	MT
Top Stories at Midday: US Construction Spending Up 0.4% in November; Avangrid-PNM Resources Deal Terminated; Terreno Realty Sells California Property for $15.9 Million; ImmunityBio Secures $320 Million Investment	Jan. 02	MT
ImmunityBio, Inc. announced that it has received $9.999194 million in funding	Dec. 28	CI

Chart ImmunityBio, Inc.

Duration

Period

More charts

Company Profile

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - American Urological Association Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ImmunityBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.35 USD

Average target price

5 USD

Spread / Average Target

-31.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNITYBIO, INC.	+46.41%	4.98B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs